191 filings
Page 5 of 10
8-K
m24yzd4 fgp
17 Apr 19
Other Events
7:00am
8-K
s8hja8rg
28 Mar 19
Marker Therapeutics Provides Business and Clinical Update
5:09pm
8-K
7jsl9l8p rskgr
25 Feb 19
Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
8:51am
8-K
hsigen5d0 7prw0urv
15 Feb 19
Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility
4:55pm
8-K
vrx ocbdq
15 Jan 19
Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
5:15pm
8-K
4epuqa
4 Jan 19
Marker Therapeutics Provides Updates of its Lead Clinical Programs
12:34pm
8-K
bjyua
4 Dec 18
Other Events
12:00am
8-K
otky9d6 8u
3 Dec 18
Departure of Directors or Certain Officers
4:12pm
8-K
1mvr4kmb ixjpeo
27 Nov 18
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
4:58pm
8-K
8yd89ax dg3hjl
27 Nov 18
Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
9:15am
8-K
pjh tz1zldy
30 Oct 18
Other Events
4:18pm
8-K/A
thpnns9oedphd nv
29 Oct 18
Financial Statements and Exhibits
12:00am
8-K
umvxd99wfbc 1o9e
23 Oct 18
Marker Therapeutics, Inc. Announces New Executive Appointments
5:08pm
8-K
vqzaxx ffrhhyno
17 Oct 18
Tapimmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing
4:00pm
8-K
julser4qd jk7wq9f
8 Aug 18
Other Events
4:40pm
8-K
cqn53u8klpzfpnet1p
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
8-K
mlx0q90lm2vnckajq7
18 May 18
Entry into a Material Definitive Agreement
5:16pm
8-K
0n9998imqv9eezfej
15 May 18
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
6:07am
8-K
5ep3p n5q
25 Sep 17
TapImmune Appoints Peter Hoang as President and Chief Executive Officer
12:00am
8-K
4ij3j7s00ytveud2m17
5 Sep 17
Submission of Matters to a Vote of Security Holders
12:00am